Jeffrey C Miller

This inventor holds 88 USPTO granted patents and 21 published patent applications, plus 21 CIPO patents and 32 EPO patents, primarily in Genome Engineering (CPC class C12N9-22). Top assignees: Sangamo Therapeutics, Inc., Sangamo Biosciences, Inc., Dow Agrosciences LLC. Active years: 2008-2026.

USPTO Granted Patents = 88 (Patent Applications = 21)

% Patents Active = 86.4

CIPO Patents = 21 (Patent Applications = 16)

EPO Patents = 32 (Patent Applications = 50)

Average Co-Inventor Count = 3.0

ph-index = 15

Forward Citations = 1,464(Granted Patents)

Forward Citations (Not Self Cited) = 1,172(Dec 10, 2025)

Inventors with similar research interests:

🔬 See more inventors

Location History:

San Francisco, CA (US) (2011 - 2013)
Pleasanton, CA (US) (2014 - 2015)
San Leandro, CA (US) (2011 - 2016)
Richmond, CA (US) (2008 - 2023)
Brisbane, CA (US) (2023 - 2024)

Company Filing History:

51 out of 153

Sangamo Therapeutics, Inc.

patents

37 out of 160

Sangamo Biosciences, Inc.

The University of Texas System

patents

5. 2 out of 15,988

University of California

patents

where one patent can have more than one assignee

Years Active: 2008-2026

Loading Chart...

Areas of Expertise:

Genome Engineering

Artificial Nucleases

DNA-Binding Proteins

Gene Expression Regulation

Target Specific Nucleases

Huntington's Disease

Hemophilia Treatment

Genetic Modification

Zinc Finger Nucleases

Exogenous Sequence Integration

Cleavage Domains

Base Editors

88 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12653861 - METHODS AND COMPOSITIONS FOR TREATING HUNTINGTON'S DISEASE (2026-06-16),

2. 12551575 - HTT REPRESSORS AND USES THEREOF (2026-02-17),

3. 11920169 - Compositions for linking DNA-binding domains and cleavage domains (2024-03-05),

4. 11845965 - Regulation of gene expression using engineered nucleases (2023-12-19),

5. 11834686 - Engineered target specific base editors (2023-12-05),

6. 11827900 - Engineered target specific nucleases (2023-11-28),

7. 11725218 - Artificial nucleases comprising engineered cleavage half-domains (2023-08-15),

8. 11723952 - Methods and compositions for treating Huntington's Disease (2023-08-15),

9. 11661612 - DNA-binding proteins and uses thereof (2023-05-30),

10. 11634463 - Methods and compositions for treating hemophilia (2023-04-25),

11. 11608492 - Compositions for linking DNA-binding domains and cleavage domains (2023-03-21),

12. 11492643 - Methods and compositions for treatment of a genetic condition (2022-11-08),

13. 11401512 - Engineered target specific nucleases (2022-08-02),

14. 11198883 - Methods and compositions for integration of an exogenous sequence within the genome of plants (2021-12-14),

15. 11136599 - Artifical nucleases comprising engineered cleavage half-domains (2021-10-05),

Title: The Innovative Journey of Jeffrey C. Miller

Introduction: Jeffrey C. Miller, a talented inventor based in Richmond, CA (US), has made significant contributions to the field of innovation with his creative ideas and groundbreaking inventions.

Latest Patents: Jeffrey C. Miller holds several patents in various industries, including technology, healthcare, and consumer goods. His most recent patents focus on sustainable energy solutions and advanced medical devices.

Career Highlights: With a career spanning over two decades, Jeffrey C. Miller has established himself as a visionary inventor known for his ability to transform ideas into tangible products. He has worked with leading companies to bring innovative concepts to the market successfully.

Collaborations: Throughout his career, Jeffrey C. Miller has collaborated with top researchers, engineers, and designers to push the boundaries of innovation. His partnerships have led to the development of cutting-edge technologies that have revolutionized their respective industries.

Conclusion: Jeffrey C. Miller's passion for innovation, coupled with his relentless drive to create, has solidified his position as a respected inventor in the field. His dedication to pushing the limits of what is possible continues to inspire the next generation of inventors and innovators.